CTLA4 and Autoimmunity: Therefore, treatment targeting CTLA-4 or PD-1 and their ligand PD-L1 may significantly affect TFH cell function in patients receiving immune checkpoint inhibitors(ICIs) therapy, providing a link between ICI therapy and the development of secondary autoimmunity (17).